Dr. Overman Discusses Nivolumab in Patients With dMMR/MSI-H mCRC
Michael J. Overman, MD
Michael J. Overman, MD, associate professor, department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses nivolumab (Opdivo) in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC).
In an analysis of the main arm of the CheckMate-142 study, investigators evaluated the idea of using anti-PD–L1 therapy in patients with dMMR/MSI-H mCRC. Fifty-three patients received nivolumab at 3 mg/kg every 2 weeks, and the primary endpoint of this study was overall response rate per RECIST 1.1 criteria. Other endpoints included progression-free survival, overall survival, safety, and tolerability.
Overman says that patients with dMMR have a lot of mutations, which are immunogenic—leading to the hypothesis that this group would be responsive to an immune-based therapy. Results confirmed this, as nivolumab continued to provide clinically meaningful and durable responses and long-term survival in patients with dMMR/MSI-H mCRC.